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Pia Jokela2, Hannimari Kallio-Kokko2, Raisa Loginov2, Laura Mannonen2,
Eeva Ruotsalainen1, Tarja Sironen6,7, Olli Vapalahti2,6,7, Maija Lappalainen2, Hanna-
Riikka Kreivi5, Hanna Jarva2,3, Satu KurkelaID
2‡*, Eliisa Kekäläinen2,3‡
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Understanding the false negative rates of SARS-CoV-2 RT-PCR testing is pivotal for the
management of the COVID-19 pandemic and it has implications for patient management.
Our aim was to determine the real-life clinical sensitivity of SARS-CoV-2 RT-PCR.
Methods
This population-based retrospective study was conducted in March–April 2020 in the Hel-
sinki Capital Region, Finland. Adults who were clinically suspected of SARS-CoV-2 infection
and underwent SARS-CoV-2 RT-PCR testing, with sufficient data in their medical records
for grading of clinical suspicion were eligible. In addition to examining the first RT-PCR test
of repeat-tested individuals, we also used high clinical suspicion for COVID-19 as the refer-
ence standard for calculating the sensitivity of SARS-CoV-2 RT-PCR.
Results
All 1,194 inpatients (mean [SD] age, 63.2 [18.3] years; 45.2% women) admitted to COVID-
19 cohort wards during the study period were included. The outpatient cohort of 1,814 indi-
viduals (mean [SD] age, 45.4 [17.2] years; 69.1% women) was sampled from epidemiologi-
cal line lists by systematic quasi-random sampling. The sensitivity (95% CI) for laboratory
confirmed cases (repeat-tested patients) was 85.7% (81.5–89.1%) inpatients; 95.5% (92.2–
97.5%) outpatients, 89.9% (88.2–92.1%) all. When also patients that were graded as high
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suspicion but never tested positive were included in the denominator, the sensitivity (95%
CI) was: 67.5% (62.9–71.9%) inpatients; 34.9% (31.4–38.5%) outpatients; 47.3% (44.4–
50.3%) all.
Conclusions
The clinical sensitivity of SARS-CoV-2 RT-PCR testing was only moderate at best. The rela-
tively high false negative rates of SARS-CoV-2 RT-PCR testing need to be accounted for in
clinical decision making, epidemiological interpretations, and when using RT-PCR as a ref-
erence for other tests.
Introduction
During the COVID-19 pandemic a central method for limiting the spread of SARS-CoV-2 has
been the so-called “Test, Trace, Isolate” (TTI) approach promoted by the World Health Orga-
nization [1, 2]. A key feature of any laboratory test is its efficacy in detecting true positive
cases. Evidence suggests a fair analytical sensitivity for the SARS-CoV-2 RT-PCR tests available
on the market [3, 4]. However, reports suggest that clinically evident COVID-19 infections
often go undetected by SARS-CoV-2 RT-PCR testing [5–9], as estimated by e.g. networked
dynamic metapopulation models [6], and repeat-testing of patients [9].
A number of pivotal factors may decrease the overall sensitivity of testing and its usefulness
in the TTI strategy. Preanalytical pitfalls such as suboptimal specimen collection may affect
sample quality and hamper test sensitivity. Variation in viral shedding in different anatomical
locations, and temporal variation in relation to disease onset can influence detection rates [10,
11].
High false negative rate complicates controlling the epidemic but it also has implications
for healthcare settings [12]. Removal of infection control precautions in hospitalized patients
due to a false negative test causes an occupational hazard for healthcare workers and can lead
to nosocomial spread of the disease. Real-life sensitivity estimates in the initial reports [13, 14]
were limited by small sample sizes and variable testing methods and reference standards.
We decided to evaluate the clinical sensitivity of SARS-CoV-2 RT-PCR in a population-
based setting in the beginning of the epidemic with low level of transmission. To avoid bias
created by the high pretest probability of inpatients, we included in our analysis also outpa-
tients. We used manually curated clinical characteristics from a cohort of 3,008 individuals as
the gold standard for the RT-PCR test. We focused on the sensitivity of the first SARS-CoV-2
RT-PCR test since for outpatients repeated testing is not often feasible. Our analysis that uses
only non-dependent samples aims to avoid the bias created from repeated sampling of the
same individuals. Our data can be directly used to inform the practicing clinicians and epide-
miologists how well the RT-PCR performs in a low prevalence setting.
Materials and methods
Study design and participants
We present data from a retrospective study conducted from electronic, comprehensive medi-
cal records. The data were fully anonymized for the study. The study complies with the
STARD reporting guidelines [15], and it was approved by the review board of the Helsinki
University Hospital, Finland (HUS/157/2020-29), which waived the requirement for informed
consent.
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During the study period 4 March– 15 April 2020, 22,821 individuals underwent SARS--
CoV-2 RT-PCR testing with a total of 1,938 test positive specimens at HUSLAB laboratory,
Helsinki University Hospital, Finland, which serves the Helsinki Capital Area in Finland. S1
Fig shows the number of daily specimens and proportion of positive specimens at HUSLAB
during the study period.
We reasoned that the pretest probability, i.e. the probability for testing positive, would be
different for inpatients on the COVID-19 cohort wards and outpatients and decided to study
these two populations separately.
Outpatient cohort. During the study period, the tested patients were generally symptom-
atic but the criteria which prompted testing varied slightly over time (S1 Table). Initially, per-
sons returning from recognized epidemic areas and exhibiting respiratory symptoms within
14 days of return were primarily tested. The criteria were soon expanded to include symptom-
atic persons with risk factors, and all symptomatic healthcare workers. Outpatients fulfilling
testing criteria were recorded manually with some clinical details on a line list. These lists were
the most systematically collected dataset for the tested outpatients so we chose to sample our
outpatient cohort from these lists. We performed systematic (quasi-random) sampling by
including every fifth individual from the line lists. Along with practical advantages, this
approach decreased the probability of sampling dependent individuals, such as members of
the same family. Besides the clinical details on the line lists, we checked electronic medical rec-
ords for comorbidities and other demographic details. Other exclusion criteria for outpatients
were age below 18 years and residence outside of the Helsinki and Uusimaa Hospital District.
Altogether 1,814 eligible outpatients (mean [SD] age, 45.4 [17.2] years; 69.1% women; 41.2%
healthcare workers) were included in the study (Fig 1, Table 1).
Inpatient cohort. Patients with fever, respiratory or gastrointestinal symptoms, and/or
difficulty in breathing were suspected for COVID-19 and treated in designated cohort wards:
11 wards and 6 ICUs in eight hospitals (list of wards in S2 Table). All patients aged>18 years
admitted to one of the cohort wards were eligible for the study and only patients without a
SARS-CoV-2 RT-PCR performed at the HUSLAB laboratory were excluded. These inpatients
formed a consecutive case series of 1,194 individuals (mean [SD] age, 63.2 [18.3] years; 45.2%
women) (Fig 2, Table 1).
Altogether 12.3% (147/1194) of inpatients and 14.1% (256/1814) of outpatients were sam-
pled for SARS-CoV-2 RT-PCR testing more than once during a specific disease episode
(Table 1). The descriptive statistics of the tested individuals and subgroups are presented in
Tables 1 and 2 and S2 Fig.
Index testing
SARS-CoV-2 RT-PCR testing was conducted by one of the following methods (gene targets):
Cobas1 SARS-CoV-2 test kit on the CobasC1 6800 system (orf1ab and E) (Roche Diagnos-
tics, Basel, Switzerland), Amplidiag1 COVID-19 test (orf1ab and N) (Mobidiag, Espoo, Fin-
land,) and a laboratory-developed test based on a protocol recommended by WHO (N)
(non-exponential amplification curves and amplification with cycle treshold values >34 in
the laboratory-developed test were reanalysed with either Cobas or Amplidiag) [16]. The
specifics and analytical performance of these methods in our laboratory setting have been
described previously [4]. Samples were collected with nasopharyngeal swabs (FLOQSwab,
Copan, Brescia, Italy) (proportion of nasopharyngeal samples: 60% inpatients, 58% outpa-
tients) but oropharyngeal swabs were used in a proportion of patients (11.1% inpatients,
16.4% outpatients) due to global shortage of nasopharyngeal swabs. Other specimens types
(0.7% inpatients, 0.2% outpatients) were tracheal, brochial, and sputum specimens, as well as
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sinus and lung biopsies The specimen type was unknown in 28.2% of inpatients and 25.5%
of outpatients.
Samples were analysed in median 24 hours after collection. As per our laboratory’s standard
operating procedure, samples with failed results were reanalysed and only qualified results
were included. 13 weak positive results which became positive in>35 PCR cycles (7 outpa-








(including 7 weak positive) 
1st test positive 235





- COVID-19 High suspicion 428
- COVID-19 not excluded 1020
- COVID-19 not suspected 37
Excluded 83:
Not enough clinical data
available for grading
Excluded 21007:
- residence outside study region* 3126
- age under 18 yrs 1309
- 4/5 outpatients excluded in quasi-randomization 7256
- other patients not on line lists 9316
Fig 1. Selection of the outpatient cohort presented as a flowchart.
https://doi.org/10.1371/journal.pone.0251661.g001
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Table 1. Patient demographic and clinical characteristics.
Inpatients (n = 1,194) Outpatients (n = 1,814) Total (n = 3,008)
Number % Number % Number %
Sex
Male 654 54.8 560 30.9 1215 40.4
Female 540 45.2 1254 69.1 1794 59.6
Age, years
Median (IQR) 66 51–77a 43 31–56a 51 36–69a
Mean (SD) 63.2 18.3 45.4 17.2 52.5 19.7
18–19 7 19 26
20–29 58 350 408
30–39 89 411 500
40–49 128 355 483
50–59 179 336 515
60–69 213 130 343
70–79 284 126 410
80–79 173 72 245
90–100 62 15 77
100- 1 - 1
Suspect grade for COVID-19 disease
Not suspected 477 39.9 37 1.8 514 17.1
Not excluded 298 25.0 1020 58.1 1318 43.8
High suspicion 88 7.4 428 22.0 516 17.2
Laboratory confirmed 328 27.5 246 13.6 574 19.1
Not known 3 0.3 83 4.6 86 2.9
Other diagnosis confirmed
Yes 554 46.4 31 1.7 585 19.4
No 600 50.3 1646 90.7 2246 74.7
Not known 40 3.4 137 7.6 177 5.9
ICU patients 158 13.2 - 158 5.3
Number of patients by sample count during the episode
1 sample 1047 87.7 1558 85.9 2605 86.6
2 samples 104 8.7 210 11.6 314 10.4
3 samples 27 2.3 39 2.1 66 2.2
4 samples 12 1.0 7 0.4 19 0.6
5 samples 4 0.3 - 4 0.1
Total samples 1404 2123 3527
Sample type (1st sample)
Nasopharyngeal+nasal 674+43 60.0 1015+37 58.0 1689+80 58.8
Oropharyngeal 132 11.1 297 16.4 429 14.3
Tracheal+bronchial+sputum 2+2+2 0.5 0+0+1 0.1 2+2+3 0.2
Sinus+lung biopsy 1+1 0.2 2+0 0.1 3+1 0.1
Not known 337 28.2 462 25.5 799 26.6
Healthcare worker
Yes 59 b 4.9 747 b 41.2 806 26.8
No 1028 86.1 737 40.6 1765 58.7
Not known 107 9.0 330 18.2 437 14.5
Smoking
Yes 191 16.0 139 7.7 330 11.0
(Continued)
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Reference standard used in the study
Since no gold standard for COVID-19 diagnosis exists, we decided to use high clinical suspi-
cion for COVID-19 as the reference standard for the RT-PCR test. We systemically graded the
clinical suspicion for COVID-19 based on a combination of symptoms, clinical findings, and
recorded exposure to laboratory confirmed COVID-19 cases or travel history to epidemic
areas. The criteria were based on CDC’s and ECDC’s case definitions for COVID-19 in April
2020. Electronic patient records or line lists were reviewed by a team consisting of senior resi-
dents in Infectious Diseases and Clinical Microbiology, medical students, and research nurses.
Patients’ medical history, symptoms, and epidemiological information were collected into a
Microsoft Access1 database according to the pre-defined criteria. Chest X-ray and CT find-
ings indicating chest infection were recorded according to radiologist’s interpretation. The
team collecting the data were aware of the SARS-CoV-2 RT-PCR test result when collecting
the data.
The clinical suspicion for COVID-19 disease was graded as follows:
1. ‘Not suspected’ patients were deemed by the clinician as non-compatible with COVID-19
disease or were diagnosed with another acute disease.
2. ‘Not excluded’ patients had no other diagnosis recorded explaining their current symptoms,
and COVID-19 disease could not be excluded.
3. ‘High suspicion’ patients were considered to suffer from a probable COVID-19 if the physi-
cian in charge of the treatment recorded the suspicion on clinical grounds to the electronic
patient record, OR the patient fulfilled at least one of the following criteria:
a. respiratory symptoms and/or fever and/or diagnostic finding for infection in chest X-
ray/CT and travel history to epidemic regions at the time of the study i.e. Tirol/Austria,
Northern Italy, Spain, Iran, South Korea, or China during the preceding 14 days.
b. respiratory symptoms and fever and diagnostic finding in chest X-ray/CT during April
2020 (time criterion based on the changed epidemiological situation).
Table 1. (Continued)
Inpatients (n = 1,194) Outpatients (n = 1,814) Total (n = 3,008)
Number % Number % Number %
Previous 268 22.4 154 8.5 422 14.0
No 439 36.8 438 24.1 877 29.2
Not known 296 24.8 1083 59.7 1379 45.8
Comorbidities c
Yes 794 66.5 367 20.2 1161 38.6
No 342 28.6 1152 63.5 1494 49.7
Not known 58 4.9 295 16.3 353 11.7
Pregnancy, if female
Yes 11 2.0 27 2.2 38 2.1
No 480 88.9 500 39.9 980 54.6
Not known 49 9.1 727 58.0 776 43.3
a Continuous variables reported as median and IQR (non-normally distributed variables) or mean and SD (normally distributed variables).
b inpatients: 45/59 female (76,3%); outpatients: 633/747 female (84,7%).
c heart disease, hypertension, lung disease, diabetes with organ damage, chronic kidney disease, dialysis, chronic liver disease, immunodeficiency, immunosuppressive
medication or cancer.
https://doi.org/10.1371/journal.pone.0251661.t001
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(including 6 weak positive)
1st test positive 281





-COVID-19 High suspicion 88
- COVID-19 not excluded 298
- COVID-19 not suspected 477
Excluded 3:
Not enough clinical data
available for grading
Excluded 21627: 
- residence outside study region* 3126
- age under 18 yrs 1309
- outpatients and patients outside of selected COVID-
19 cohort wards 17192
Fig 2. Selection of the inpatient cohort presented as a flowchart.
https://doi.org/10.1371/journal.pone.0251661.g002
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Table 2. Patient demographic and clinical characteristics by clinical suspicion of COVID-19 in inpatients (A) and outpatients (B). Three patients in the inpatient
cohort could not be classified. ‘Not suspected’: deemed by the clinician as non-compatible with COVID-19 disease or were diagnosed with another acute disease; ‘Not
excluded’: no other diagnosis recorded explaining their current symptoms, and COVID-19 disease could not be excluded. ‘High suspicion’: physician in charge of the treat-
ment recorded the suspicion on clinical grounds to the electronic patient record, OR the patient fulfilled a set of pre-defined clinical and exposure criteria (see Methods);















P Value COVID-19 High Suspicion vs.
Covid lab.confirmed
Number % Number % Number % Number %
Sex .16a
Male 255 53.5 172 57.7 41 46.6 183 55.8
Female 222 46.5 126 42.3 47 53.4 145 44.2
Age, years








Range 18–103 18–96 18–96
Other diagnosis confirmed
Yes 448 93.9 92 30.9 ND ND
No 17 3.6 184 61.7 ND ND
Not known 12 2.5 22 7.4 ND ND
Influenza A, Influenza B, and RSV
Total tested 395 82.8 261 87.6 79 89.8 186 56.7 < .001a
Influenza A positive 6 1.3 0 0 0 0 NA
Influenza B positive 4 0.8 0 0 0 0 NA
RSV positive 24 3.1 9 3.0 0 0 NA
Other virus finding
Total tested 15 3.1 20 6.7 7 8.0 1 0.3 < .001a
Coronavirus 229E/NL63/OC43 2 - - NA
Rhinovirus - 1 - - NA
Rhinovirus and Coronavirus 229E/NL63/
OC43
1 - - NA
ICU patients 44 9.2 22 7.4 7 7.8 82 25.0 < .001a
Time between symptom onset and first
SARS-CoV-2 RT-PCR test
<1 day 152 31.9 71 23.8 7 8.0 22 6.7
1–2 days 112 23.5 59 19.8 12 13.6 55 16.8
3–4 days 46 9.6 39 13.1 15 17.0 50 15.2
5–6 days 29 6.1 28 9.4 7 8.0 58 17.7
7–14 days 61 12.8 54 18.1 38 43.2 132 40.2
>14 days 38 8.0 31 10.4 7 8.0 8 2.4
No data 39 8.2 16 5.4 2 2.3 3 0.9
Fever < .001c
Yes 233 48.8 193 64.8 67 76.1 300 91.5
No 187 39.2 85 28.5 20 22.7 21 6.4
Not known 57 11.9 20 6.7 1 1.1 7 2.1
Upper respiratory symptoms .86a
Yes 119 24.9 83 27.9 38 43.2 131 39.9
No 218 45.7 109 36.6 23 26.1 90 27.4
Not known 140 29.4 106 35.6 27 30.7 107 32.6
Lower respiratory symptoms .52c
(Continued)
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Table 2. (Continued)
Yes 282 59.1 240 80.5 84 95.5 299 91.2
No 134 28.1 39 13.1 2 2.3 14 4.3
Not known 61 12.8 19 6.4 2 2.3 15 4.6
Infectious finding in chest X-ray/CT .33c
Yes 78 16.4 103 34.6 72 81.8 266 81.1
No 337 70.6 181 60.7 12 13.6 55 16.8
Not done 28 5.9 9 3.0 2 2.3 2 0.6
Not known 34 7.1 5 1.7 2 2.3 5 1.5
Altered sense of smell .24a
Yes 3 0.6 2 0.7 3 3.4 27 8.2
No 59 12.4 24 8.1 13 14.8 38 11.6
Not known 415 87.0 272 91.3 72 81.8 263 80.2
Gastrointestinal symptoms .03a
Yes 137 28.7 65 21.8 32 36.4 155 47.3
No 146 30.6 109 36.6 21 23.9 90 27.4
Not known 194 40.7 124 41.6 35 39.8 83 25.3
Thrombosis .26c
Yes 18 3.8 9 3.0 6 6.8 10 3.0
No 261 54.7 208 69.8 56 63.6 220 67.1
Not known 198 41.5 81 27.2 26 29.5 98 29.9
Contact in 14 days to symptomatic COVID-
19
.03a
Yes 15 3.1 10 3.4 18 20.5 117 35.7
No 214 44.9 124 41.6 33 37.5 101 30.8
Not known 248 52.0 164 55.0 37 42.0 110 33.5
Travel in 14 days .11a
To defined risk areas d 7 1.5 3 1.0 4 4.5 28 8.5
Other 11 2.3 12 4.0 10 11.4 19 5.8
No travel abroad 300 62.9 208 69.8 55 62.5 227 69.2
Not known 159 33.3 75 25.2 19 21.6 54 16.5
Healthcare worker: .13c
Yes 10 2.1 8 2.7 5 5.7 36 11.0
No 432 90.6 269 90.3 68 77.3 256 78.0
Not known 35 7.3 21 7.0 15 17.0 36 11.0
Clinical severity grade .23a
Low ND ND - 2 0.6
Medium ND ND 62 70.5 198 60.4
Severe e ND ND 23 26.1 120 36.6
Not known ND ND 3 3.4 8 2.4
Smoking .001a
Yes 106 22.2 57 19.1 13 14.8 14 4.3
Quitted 95 19.9 87 29.2 19 21.6 66 20.1
No 137 28.7 88 29.5 37 42.0 177 54.0
Not known 139 29.1 66 22.1 19 21.6 71 21.6
Comorbidities .19c
Yes 364 76.3 230 77.2 49 54.4 150 45.7
No 80 16.8 66 22.1 39 43.3 158 48.2
Not known 33 6.9 2 0.7 2 2.2 20 6.1
(Continued)
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P Value COVID-19 High Suspicion vs.
Covid lab.confirmed
Number % Number % Number % Number %
Sex .004a
Male 17 45.9 256 25.1 151 35.3 115 46.7
Female 20 54.1 764 74.9 277 64.7 131 53.3
Age, years




40 30–51 42 31–55
Range 18–89 18–98 18–91 18–94
Other diagnosis confirmed .13c
Yes 29 78.4 - - -
No 7 18.9 957 93.8 417 97.4 234 95.1
Not known 1 2.7 63 6.2 11 2.6 12 4.9
Influenza A, Influenza B and RSV
Total tested 21 56.8 104 10.2 58 13.6 17 6.9 .01a
Influenza A positive 3 0 0 0 NA
Influenza B positive 4 0 0 0 NA
RSV positive 2 0 0 0 NA
Other virus finding
Total tested 4 2 3 1 >.99c
Rhinovirus 1 - - - NA
Time between symptom onset and first
SARS-CoV-2 RT-PCR test
<1 day 5 13.5 28 2.7 14 3.3 15 6.1
1–2 days 12 32.4 260 25.5 120 28.0 74 30.1
3–4 days 4 10.8 203 19.9 84 19.6 52 21.1
5–6 days 7 18.9 117 11.5 48 11.2 30 12.2
7–14 days 3 8.1 246 24.1 98 22.9 40 16.3
>14 days 1 2.7 65 6.4 19 4.4 5 2.0
No data 5 13.5 101 9.9 45 10.5 30 12.2
Fever < .001a
Yes 11 29.7 122 12.0 55 12.9 90 36.6
No 16 43.2 337 33.0 144 33.6 59 24.0
Not known 10 27.0 561 55.0 229 53.5 97 39.4
Upper respiratory symptoms .81c
Yes 10 27.0 371 36.4 179 41.8 102 41.5
No 7 18.9 15 1.5 6 1.4 5 2.0
Not known 20 54.1 634 62.2 243 56.8 139 56.5
Lower respiratory symptoms .51a
Yes 19 54.3 440 43.1 198 46.3 123 50.0
No 4 10.8 29 2.8 11 2.6 8 3.3
Not known 14 37.8 551 54.0 219 51.2 115 46.7
Infectious finding in chest X-ray/CT .18c
Yes 1 2.7 4 0.4 4 0.9 5 2.0
No 14 37.8 57 5.6 9 2.1 11 4.5
(Continued)
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Table 2. (Continued)
Not done 16 43.2 613 61.0 244 57.0 130 52.8
Not known 6 16.2 346 33.9 171 40.0 100 40.7
Altered sense of smell < .001c
Yes 1 2.7 5 0.5 8 1.9 23 9.3
No 1 2.7 2 0.2 - 1 0.4
Not known 35 94.6 1013 99.3 420 98.1 222 90.2
Gastrointestinal symptoms .19c
Yes 2 5.4 55 5.4 15 3.5 14 5.7
No 5 13.5 9 0.9 1 0.2 2 0.8
Not known 30 81.1 956 93.7 412 96.3 230 93.5
Thrombosis .49
Yes - - - -
No 17 45.9 117 11.5 36 8.4 25 10.2
Not known 20 54.1 903 88.5 392 91.6 221 89.8
Contact in 14 days to symptomatic COVID-
19
< .001a
Yes 7 18.9 3 0.3 299 69.9 141 57.3
No 12 32.4 341 33.4 32 7.5 16 6.5
Not known 18 48.6 676 66.3 97 22.4 89 36.2
Travel in 14 days .005a
To defined risk areas d 3 8.1 12 1.2 131 30.6 49 19.9
Other - 197 19.3 16 3.7 16 6.5
No travel abroad 24 64.9 626 61.4 205 47.9 121 49.2
Not known 10 27.0 185 18.1 76 17.8 60 24.4
Healthcare worker: < .001a
Yes 6 16.2 533 52.3 118 27.6 59 24.0
No 28 75.7 398 39.0 170 39.7 127 51.6
Not known 3 8.1 89 8.7 140 32.9 60 24.4
Clinical severity grade: .001c
Low ND ND 423 98.8 229 93.1
Medium ND ND 2 0.5 2 0.8
Severe ND ND - -
Not known ND ND 3 0.7 15 6.1
Smoking: .80c
Yes 3 8.1 92 9.0 29 6.8 12 4.9
Quitted 8 21.6 107 10.5 24 5.6 14 5.7
No 9 24.3 270 26.5 95 22.2 55 22.4
Not known 17 45.9 551 54.0 280 65.4 165 67.1
Comorbidities: >.99a
Yes 19 5.4 248 24.3 56 13.1 33 13.4
No 15 40.5 653 64.0 285 66.6 163 66.3
Not known 3 8.1 119 11.7 87 20.3 50 20.3
a Chi-squared test.
b Continuous variables reported as median (IQR).
c Fisher exact test.
d defined risk areas were Austria Tiroli, Northern Italy, Spain, China and South Korea.
e admitted to ICU OR recorded respiratory rate of�30/min OR oxygen saturation�85% (with or without supplemental oxygen at any stage).
ND = not determined.
NA = not applicable.
https://doi.org/10.1371/journal.pone.0251661.t002
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c. respiratory or gastrointestinal symptoms or fever or diagnostic finding in chest X-ray/
CT and a close contact with a laboratory confirmed COVID-19 patient during the pre-
ceding 14 days prior to disease onset.
4. ‘Laboratory confirmed’ patients (regardless of their clinical presentation) were those indi-
viduals that tested positive for SARS-CoV-2 RT-PCR during the study period. At the time
of the study, only symptomatic individuals were tested, so the laboratory confirmed group
does not include any asymptomatic cases.
Sample size calculation
We estimated the minimum sample size needed for outpatients based on Bujang et al. [17],
with a minimal statistical power of 80% and type I error<0.05. Sample size calculation for sen-
sitivity requires a prevalence estimation in the target population. During the study period, the
median positivity rate was 9.6% (S1 Fig) so we estimated a 10% prevalence for the tested popu-
lation. Published estimates from small cohorts [18, 19] available at the time reported sensitivity
of the SARS-CoV-2 RT-PCR to be on average 70%. Based on these estimates the minimum
sample size of outpatients for null hypothesis of sensitivity of 70% was 1,550. We performed
another sample size calculation by using the nomogram described by Carley et al. [20] which
accounts for confidence intervals (CI): with CI of 93% and prevalence 10%, 70% sensitivity
would require a minimum sample size of 1,600.
Group comparisons
To detect if the high suspicion and the laboratory confirmed groups were comparable and if
there would be significant confounding factors between the groups that were used for sensitiv-
ity calculations, we compared demographic and clinical characteristics between them (Tables
1 and 2). To compare these two groups with respect to the categorical variables, we used the
Pearson’s Chi-squared test without or with Yate’s correction for continuity or the Fisher’s
exact test, as appropriate. For the extensive contingency tables with the excess of small
(expected) frequencies, we assessed the simulated p-value of the Fisher’s test based on 20,000
replicates. The differences in the age distribution were assessed using the Mann-Whitney U-
test. These comparisons were performed separately within the inpatients and outpatients.
Analysis of sensitivity
Two approaches were deployed to calculate SARS-CoV-2 RT-PCR sensitivity: repeat-tested
laboratory confirmed patients, and patients with a high clinical suspicion of COVID-19.
For the laboratory confirmed patients, the sensitivity values were calculated based on the
first RT-PCR test of each patient. All patients who tested RT-PCR positive during a specific
disease episode were considered laboratory confirmed. Of these, the first samples with a nega-
tive RT-PCR test result were considered false negatives, while the first samples with a positive
result were considered true positives. The same disease episode would include samples taken
�14 days apart.
For the high clinical suspicion group, the sensitivity was calculated by considering those
patients that were graded as high suspicion but never tested positive as false negative cases.
The 95% CIs for (binomial) sensitivity were calculated by using the Wilson-Score method,
which is based on inverting the z-test for a single proportion and provides more reliable cover-
age than the alternatives. We performed comparisons of sensitivity between the subgroups by
using the independent sample tests for binomial proportions, including Chi-squared test with-
out or with Yate’s correction for continuity or the Fisher’s exact test, as appropriate. For the
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extensive contingency tables with the excess of small (expected) frequencies, we assessed the
simulated p-value of the Fisher’s test based on 20,000 replicates. We set the confidence level at
5%. All calculations were performed using the R software.
Results
Demographics of the study population and clinical comparison between
study groups
In all, 3,008 individuals were eligible for this study (Figs 1 and 2): 1,814 outpatients and 1,194
inpatients. Altogether 83 eligible outpatients (4.6%) and 3 inpatients (0.3%) were excluded
from the final analysis due to insufficient data for the grading of clinical suspicion.
The inpatients were on average older than outpatients, comorbidities were more common,
and the male sex was slightly overrepresented (Table 1). Healthcare workers and women were
overrepresented in the outpatient population reflecting the distribution of the whole tested
population, as reported before [21].
All patients were categorized by a clinical grade of suspicion (not suspected / not excluded /
high suspicion / laboratory confirmed) for COVID-19 based on criteria described in Methods
(Table 1). To detect if our grading created systematic bias or if there were significant con-
founding factors present between the groups, we compared test negative patients that were
deemed as high suspicion to laboratory confirmed patients (Table 2). There were no significant
differences in sex or age distribution between these groups, but patients treated in the intensive
care unit were overrepresented in the laboratory confirmed hospitalized patients (Table 2A).
Laboratory confirmed patients were also more often febrile and had had contact with labora-
tory confirmed symptomatic COVID-19 cases (Table 2A and 2B). Laboratory confirmed
patients also had more often gastrointestinal symptoms than patients in the high suspicion
group (Table 2A and 2B).
In the outpatients, the high suspicion group had a higher proportion of females and health-
care workers compared to laboratory confirmed cases. This was expected based on the overall
higher testing rate of both [21]. Again, the laboratory confirmed cases were more often febrile.
Since our grading criteria included exposure to symptomatic COVID-19 patients or travel to
epidemic areas, these factors were more common in the high suspicion group that tested nega-
tive, than in the laboratory confirmed group (Table 2B).
Sensitivity of the first SARS-CoV-2 RT-PCR in inpatients and outpatients
The sensitivity of SARS-CoV-2 RT-PCR was calculated with two different denominators
(Table 3). We first calculated the sensitivity with laboratory confirmed cases, i.e. repeat-tested
patients as a denominator, yielding the highest sensitivity estimates in this study, as follows:
85.7% for inpatients; 95.5% for outpatients, and 89.9% for all. Due to low number of repeat-
tested patients (N = 11), the calculation for outpatients here is unreliable.
The sensitivity was then calculated by including in the denominator patients that were
graded as high suspicion but never tested positive (from one or more tests conducted within
the study period), yielding the following sensitivity values: 67.5% for inpatients, 34.9% for out-
patients and 47.3% for all. Thus, the lowest calculated sensitivity estimate in this study was for
outpatients with high suspicion.
The delay between disease onset and testing was longer for inpatients than outpatients
(Table 2). We could not detect a significant difference in the delay to first test between the lab-
oratory confirmed cases and the high suspicion group in either cohort (S3 Fig, Fisher’s Exact
Test p = 1 when “No data” category excluded). However, for inpatients, information on the
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delay was missing more often in the high suspicion group (2.3%) compared to the laboratory
confirmed (0.9%, p = 0.026) (Table 2). For outpatients, information on the delay was missing
less often in the high suspicion group (10.5%) as compared to the laboratory confirmed (12.2%
p = 0.026) (Table 2).
We could not detect a significant difference between the sensitivity of nasopharyngeal and
oropharyngeal samples in the inpatients (p = 0.51, Chi-squared test), outpatients (p = 0.22) or
all patients (p = 0.66) (S3 Table; S4 Fig). However, data on the specimen type was missing in
20.4% (inpatients) and 17.4% (outpatients) of the cases.
Delay between symptom onset and positive test result
To estimate the delay from disease onset for highest clinical sensitivity for SARS-CoV-2
RT-PCR, we calculated sensitivities for different time frames. To achieve reliable group sizes,
both cohorts were pooled together. There was no significant difference in the test sensitivity
according to delay from onset, calculated for the laboratory confirmed cases alone, and with
the high clinical suspicion group included (P = 0.1013 Fisher’s Exact Test for Count Data with
simulated p-value, based on 20000 replicates; Fig 3). Detailed sensitivity calculations per delay
from disease onset are presented in S4 Table.
Discussion
Wide-spread testing and contact tracing together with social distancing has been promoted as
the tool that prevents new lockdowns–without clear understanding of how well the SARS--
CoV-2 RT-PCR test performs. Here, we used clinical suspicion as the gold standard to estimate
the clinical sensitivity of the test. We also included a sensitivity calculation based on the
repeat-tested individuals where RT-PCR acts as the gold standard for itself.
A previous large-scale sensitivity estimate for SARS-CoV-2 molecular testing was based
only on repeat-tested individuals [9, 22]. This approach overestimates the sensitivity. Repeated
testing is done mostly on inpatients who have a strong clinical suspicion, rendering high pre-
test probability. We sought to overcome this limitation by including a large cohort of outpa-
tients. From an epidemiological point-of-view, understanding the clinical sensitivity for mild
cases is important. An RT-PCR sensitivity of 64% for exposed family members systemically
tested with serology was recently reported [23]. This is in line with our sensitivity estimation
for inpatients. Another small study found an 86.2% RT-PCR sensitivity in symptomatic
COVID-19 patients in comparison with convalescent antibody [24]. Interestingly, a recent
Cochrane meta-analysis on thoracic imaging of COVID-19 patients found an 87.9% pooled
sensitivity for chest CT and 80.6% for chest X-ray [25]. However, diagnostic imaging is mainly
performed on inpatients that can overestimate the sensitivity. Our analysis was done in a low
Table 3. Sensitivity calculations for the first SARS-CoV-2 RT-PCR test.
Denominator Inpatients Outpatients All
COVID-19 Laboratory confirmed patients N/N 281/328 235/246 516/574
Sensitivity (%) 85.7% 95.5% 89.9%
95% CI (81.5–89.1%) (92.2–97.5%) (88.2–92.1%)
COVID-19 Laboratory confirmed + High suspicion patients N/N 281/416 235/674 516/1090
Sensitivity (%) 67.5% 34.9% 47.3%
95% CI (62.9–71.9%) (31.4–38.5%) (44.4–50.3%)
The numerator for all calculations is the number of patients that tested positive with first sample.
https://doi.org/10.1371/journal.pone.0251661.t003
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prevalence setting. Thus, the negative predictive value for the RT-PCR test was high (89%) for
the outpatients even though the clinical sensitivity was low (35%), assuming all COVID-19
excluded cases were true negatives. High false negative rates reduce the negative predictive
value of testing. This is particularly problematic when the prevalence of the disease increases.
In such settings, it will impair effective use of wide-spread testing.
For health-care facilities the message of our data is different: a single negative result cannot
be trusted to rule out COVID-19 in patients with suitable symptoms. Our data show that the
sensitivity of the repeat-tested inpatients was high (86%), and in line with previous reports on
repeated testing [9, 22]. When the sensitivity of the COVID-19 PCR test was judged based on
the laboratory confirmed and high clinical suspicion patients the estimated sensitivity of the
test dropped to around 68%. Our results emphasize the importance of repeated sampling but it
also highlights the importance to evaluate the patient’s clinical presentation carefully.
This study estimated test sensitivity both with repeat-tested patients and by using clinical
suspicion as a gold standard. The estimated sensitivity (89.9%) for repeat-tested patients is
probably an overestimation: samples from a single individual are not independent and there is
often a clear clinical rationale, i.e. high clinical suspicion for COVID-19 that necessitates the
repeated testing, leading to increased pretest probability. In addition, hospitalized patients
often present with a more severe disease with higher viral loads and longer viral nucleic acid
shedding than individuals with mild symptoms [26], again leading to overestimation of test
sensitivity. Our data shows that laboratory confirmed cases in both outpatients and hospital-
ized patients were more often febrile than the high clinical suspicion cases even though almost
all other symptoms were comparable between the groups. This could indicate that the more
severe cases were more often detected with RT-PCR. In contrast, the estimate which included
both laboratory confirmed and high suspicion outpatients (34.9%), is likely an underestima-
tion as COVID-19 symptoms are shared with other respiratory infections. In all, we conclude
Fig 3. Clinical SARS-CoV-2 RT-PCR sensitivity estimates in the laboratory confirmed, and in the laboratory
confirmed and high suspicion group combined, presented according to delay (days) from symptom onset to
sampling.
https://doi.org/10.1371/journal.pone.0251661.g003
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that the group which included both laboratory confirmed and high suspicion inpatients likely
yielded the most realistic sensitivity estimate (67.5%).
Generally the first symptomatic days are considered best for virus detection from the upper
airways [27, 28]. Due to the limited sample size our analysis could not detect a definitive time-
point for highest sensitivity. However, even with this under-powered estimation, we should
have detected major trends.
The study had several limitations. All patients were considered symptomatic so the esti-
mates cannot be generalized to asymptomatic patients. The clinical criteria were set based on
the information available in April 2020. While the core symptoms have remained the same,
understanding of COVID-19 presentations has since increased. The clinical diagnosis of
COVID-19 is notoriously hard as the symptoms are variable and overlap with many other sim-
ilar conditions. In the hospitalized patients the testing coverage for other viral pathogens was
extensive, and circulation of influenza and RSV was very limited at the time. However, most
outpatients in this study were not tested for other potential viral pathogens. Potential informa-
tion bias was introduced by the sometimes undetailed clinical records of outpatients. Report-
ing bias for more detailed symptoms most likely exists, especially for the laboratory confirmed
outpatient cases. The specimen types recorded in the sample referrals may have contained
errors. While pre-defined clinical criteria were used for grading, the data were collected retro-
spectively and the data collectors were aware of the index test result.
Large scale molecular testing has permanently changed the practice of clinical microbiol-
ogy. RT-PCR for SARS-CoV-2 detection has many limitations as a labor intensive test with a
relatively slow throughput. This has led to unbearable delays in results. Multiple solutions are
being developed: point-of-care viral antigen detection [29], sample pooling [30], and self-sam-
pling [31]. All these approaches, which use RT-PCR as a reference, quite consistently report
lower sensitivity than RT-PCR. It is thus evident that all our current testing options are far
from optimal in detecting all COVID-19 cases. In controlling of the ongoing pandemic, we
need focused research to find an appropriate balance in the tradeoff between test sensitivity,
and speed and ease of testing in each epidemiological setting.
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Validation: Elisa Kortela, Vesa Kirjavainen, Maarit J. Ahava, Suvi T. Jokiranta, Anna But, Anu
E. Jääskeläinen, Annemarjut J. Jääskeläinen, Asko Järvinen, Pia Jokela, Hannimari Kallio-
PLOS ONE Clinical sensitivity of SARS-CoV-2 RT-PCR
PLOS ONE | https://doi.org/10.1371/journal.pone.0251661 May 21, 2021 17 / 19
Kokko, Raisa Loginov, Eeva Ruotsalainen, Tarja Sironen, Olli Vapalahti, Maija Lappalai-
nen, Hanna-Riikka Kreivi, Hanna Jarva, Satu Kurkela, Eliisa Kekäläinen.
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Writing – review & editing: Elisa Kortela, Vesa Kirjavainen, Maarit J. Ahava, Suvi T. Jokir-
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